The pharmaceutical giant is set to release quarterly results before the bell Wednesday, with Wall Street anticipating another period of blockbuster revenue growth driven by its GLP-1 drugs.
Medical device giant Boston Scientific (BSX) is scheduled to release its fourth-quarter financial results before market open on Wednesday, with Wall Street anticipating continued strong revenue growth and another potential earnings beat.
All eyes are on Flex (NASDAQ: FLEX) as it prepares to release its fourth-quarter earnings before the market opens on Wednesday. The contract manufacturing leader has consistently outperformed Wall Street's revenue expectations, but can it do so again in a challenging macro environment?
Twist Bioscience's proprietary silicon-based DNA manufacturing platform is driving double-digit revenue growth and margin expansion, positioning the synthetic biology tools provider on a clear path to adjusted EBITDA breakeven by fiscal 2026.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
French biotech Abivax sees renewed investor interest following strong Phase 3 data for its oral therapy obefazimod in hard-to-treat ulcerative colitis, with analysts pointing to a clear path to regulatory approval and significant market potential.
After a significant rebound, ACADIA Pharmaceuticals (ACAD) shares present a conundrum for investors. While a discounted cash flow model suggests deep undervaluation, the stock's volatile history and mixed performance metrics demand a closer look at the underlying narrative.
Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.
Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
A detailed analysis of Alcon Inc. (ALC) highlights the company's market leadership, margin expansion potential, and the upcoming catalyst of its UNITY surgical system, presenting a compelling bull case for the eye care specialist.
ResMed Inc., the sleep therapy giant, faces a pivotal moment. While benefiting from a competitor's recall and a growing market funnel, emerging oral treatments and shifting dynamics pose fresh challenges to its long-held CPAP business model.
An analysis of the bullish investment case for DaVita Inc. highlights its entrenched market position and cash flow discipline, while underscoring the significant regulatory and leverage risks inherent in the kidney care sector.
As Becton Dickinson's complex Reverse Morris Trust transaction nears its 2026 close, analysts argue the market is overlooking a significant value catalyst and an attractively priced remaining business.
Personalis, Inc. (NASDAQ: PSNL) is attracting investor attention with its ultra-sensitive NeXT Personal blood test, capable of detecting cancer recurrence far earlier than standard methods. With a key distribution deal and anticipated Medicare reimbursement, the company could be on the cusp of a significant inflection point.
A new national survey reveals a significant majority of American voters believe the rollout of artificial intelligence is happening too rapidly, coupled with profound doubts about federal regulators' capacity to oversee the technology effectively.
Vaxcyte (PCVX) bolsters its financial position with a successful public offering, channeling fresh capital into pivotal late-stage trials for its broad-spectrum pneumococcal vaccine candidate, VAX-31, in both adults and infants.
Pfizer has secured global rights to Novavax's Matrix-M adjuvant technology, aiming to develop new vaccines for infectious diseases as it seeks to diversify its portfolio beyond pandemic-related sales.
Once an open-source developer tool, GitLab has transformed into a unified AI-powered DevSecOps platform. With strong enterprise adoption and a focus on solving the 'AI Paradox,' the company presents a compelling, if competitive, growth story for investors.
Insulet Corporation (NASDAQ: PODD), the maker of the tubeless Omnipod insulin delivery system, is drawing investor attention with a potent mix of surging cash flow, market expansion, and a recurring revenue model. As the company capitalizes on recent regulatory wins and international growth, we examine the bull case and the risks ahead.
